by Raynovich Rod | Sep 9, 2021 | 2024-25 Life Science Portfolios, Biopharmaceuticals
Update-1 Five days of selling but looks like routine re-balancing at market highs. NASDAQ leads way down 0.7% Whether it is concerns about Washington or a seasonal buyers strike or even an extended summer vacation who knows? The 3.3% drop in AAPL on App Store ruling...
by Raynovich Rod | Aug 30, 2021 | 2024-25 Life Science Portfolios
Update-1 3:45P 9/1 FDA issues warning on JAK Inhibitor drug class. ABBV down 7%., PFE and LLY drugs also affected. Small cap rally intact: CRSP,CYRX, VCYT. Quidel (QDEL) up 5.45% on need for more COVID tests. ARKG and XBI up about 1.5%. Mid-caps all green. IBB up...
by Raynovich Rod | Jul 12, 2021 | 2024-25 Life Science Portfolios, Healthcare stocks
Update-3 JY 20…a good reversal day! Our healthcare portfolio strategy is working well even on volatile days.All major averages were up about 1.5% today and most biotechs did better.The XLV was up 1.2% to $128.82.We will post a new article at the end of the...
by Raynovich Rod | Jul 2, 2021 | 2024-25 Life Science Portfolios
Update-1 8:45am Vacation through Friday:Asia down, Futures down over 1% on growth concerns. Technicals look toppy on ARKG and XBI. New Mid-Cap Biotech Picks Momentum indicators for tracking and trading:ARKG and XBI. All three recent mid-cap biotech picks are up since...
by Raynovich Rod | Jun 18, 2021 | 2024-25 Life Science Portfolios, Biopharmaceuticals
Update-1 6/18 On a Risk-Off Day with Selling at Close NASDAQ down 0.92% to 14030, ARKG down 0.62%,IBB down 0.185, XBI down 0.6%, XLV down 1.14% at $123.74. iShares Medical Device ETF (IHI) down 0.65% at $350.67. Focus Mid-Cap Life Science Stocks: CYRX down 1.77% to...
by Raynovich Rod | May 9, 2021 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
Update-3 11:20a 5/17. Large Caps continue to Look Good; Defensive with dividends and a little growth. ~1% movers as of mid-day trading: AZN, BIIB,GILD, GSK, REGN. IBB lags. Update-2 1:15p EDT Biotech stocks remain sluggish as NASDAQ rally slumps to red. Large caps...
by Raynovich Rod | Mar 8, 2021 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
Update on rally day 3/9/21 1:22p Biotech and Healthcare Movers per Post Tech stocks rally on reversal trade. Biopharma positioned between value and moderate growth. COVID Vaccine stocks all up big BNTX CVAC NVAX MRNA. Small caps continue in uptrend ; IJR IWC IWM....
by Raynovich Rod | Mar 3, 2021 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, Macro
Update-1 3/5/21…2:30p-Large Cap Biopharmas Firming Up See our last Large Cap Review . IBB up 0.73% at $148 handle. Regeneron up 3% off bottom, FWD PE 11.31, P/S 5.7, 11.75 QtQ sales growth . Nice moves in AMGN, BIIB, GILD, GSK, LLY. Review your large caps!...
by Raynovich Rod | Feb 22, 2021 | 2024-25 Life Science Portfolios, Biopharmaceuticals
Update-2 2/25…Correction seems more real just after market indices hit new highs yesterday: QQQ down 3.49% piercing 200 MA at $312.83. An unusual down day when both bonds and stocks take a hit over concerns about rapidly rising 10 yr TSY rates now yielding...
